Trial Profile

A Phase 1 clinical trial is a single-center, randomized, double-blind, placebo-controlled, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetic profile of LY03021 in healthy subjects for Major-depressive-disorder

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Nov 2024 New trial record
11 Nov 2024 According to Luye Pharma media release, the company announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for LY03021 for the treatment of Major Depressive Disorder (MDD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com